Additional Payments Receivable On Milestone Achievements

No definition available.

Name:	aria_AdditionalPaymentsReceivableOnMilestoneAchievements
Namespace Prefix:	aria_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Additional Third Party Funding Available

+ References

No definition available.

+ Details

Name:	aria_AdditionalThirdPartyFundingAvailable
Namespace Prefix:	aria_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Contract Amount

+ References

No definition available.

+ Details

Name:	aria_ContractAmount
Namespace Prefix:	aria_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Extension Period For Pediatric Exclusivity

+ References

No definition available.

+ Details

Name:	aria_ExtensionPeriodForPediatricExclusivity
Namespace Prefix:	aria_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

License Arrangement with Counterparty, Contribution Receivable

+ References

No definition available.

+ Details

Name:	aria_LicenseArrangementwithCounterpartyContributionReceivableForYearOne
Namespace Prefix:	aria_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

License Arrangement with Counterparty, Contribution Receivable For Year Two

+ References

No definition available.

+ Details

Name:	aria_LicenseArrangementwithCounterpartyContributionReceivableForYearTwo
Namespace Prefix:	aria_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Royalty Payment Rate

+ References

No definition available.

+ Details

Name:	aria_RoyaltyPaymentRate
Namespace Prefix:	aria_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Term Of License Fees

+ References

No definition available.

+ Details

Name:	aria_TermOfLicenseFees
Namespace Prefix:	aria_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of countries in which the entity operates as of balance sheet date.

+ References

No definition available.

+ Details

Name:	us-gaap_NumberOfCountriesInWhichEntityOperates
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Cash received on stock transaction after deduction of issuance costs.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

+ References

No definition available.

+ Details

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=aria_PdlBiopharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TransactionTypeAxis=aria_ScenarioTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_AffiliatedEntityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=aria_ARIADPharmaceuticalsL.P.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_OtherCommitmentsAxis=aria_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=aria_IncyteCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Subsequent Events (Details)	May. 09, 2016 USD ($) country	Jul. 31, 2015 USD ($)
PDL BioPharma \| Scenario 2
Subsequent Event [Line Items]
Contract amount		$ 100,000,000
Subsequent event \| Affiliated entity \| ARIAD Pharmaceuticals
Subsequent Event [Line Items]
Number of other countries in which Iclusig is commercialized \| country	22
Consideration received for sale of stock	$ 140,000,000
Subsequent event \| PDL BioPharma \| Scenario 2
Subsequent Event [Line Items]
Amount of additional funding (up to)	40,000,000
Subsequent event \| License agreement \| Incyte
Subsequent Event [Line Items]
Additional milestone payments (up to)	135,000,000
Contribution receivable for funding trials in 2016 (up to)	7,000,000
Contribution receivable for funding trials in 2017 (up to)	$ 7,000,000.0
Potential extension period for pediatric exclusivity	6 months
Term of license fee	7 years
Subsequent event \| License agreement \| Incyte \| Minimum
Subsequent Event [Line Items]
Royalty payment rate (as a percent)	32.00%
Subsequent event \| License agreement \| Incyte \| Maximum
Subsequent Event [Line Items]
Royalty payment rate (as a percent)	50.00%